AR112757A1 - IMMUNOGENIC COMPOSITIONS - Google Patents
IMMUNOGENIC COMPOSITIONSInfo
- Publication number
- AR112757A1 AR112757A1 ARP180101929A ARP180101929A AR112757A1 AR 112757 A1 AR112757 A1 AR 112757A1 AR P180101929 A ARP180101929 A AR P180101929A AR P180101929 A ARP180101929 A AR P180101929A AR 112757 A1 AR112757 A1 AR 112757A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunogenic
- polypeptide
- cea
- nucleic acid
- compositions
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 11
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 abstract 2
- 102100034256 Mucin-1 Human genes 0.000 abstract 2
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona: (a) polipéptidos de CEA inmunogénicos aislados; (b) moléculas de ácidos nucleicos aisladas que codifican (i) un polipéptido de CEA inmunogénico, (ii) un polipéptido de CEA inmunogénico y un polipéptido de MUC1 inmunogénico, (iii) un polipéptido de CEA inmunogénico y un polipéptido de TERT inmunogénico o (iv) un polipéptido de CEA inmunogénico, un polipéptido de MUC1 inmunogénico y un polipéptido de TERT inmunogénico; (c) composiciones que comprenden una molécula de ácidos nucleicos aislada; y (d) métodos relacionados con usos de los polipéptidos de CEA inmunogénicos, moléculas de ácidos nucleicos y composiciones.The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide or ( iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods related to uses of immunogenic CEA polypeptides, nucleic acid molecules, and compositions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531227P | 2017-07-11 | 2017-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112757A1 true AR112757A1 (en) | 2019-12-11 |
Family
ID=69024783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101929A AR112757A1 (en) | 2017-07-11 | 2018-07-11 | IMMUNOGENIC COMPOSITIONS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR112757A1 (en) |
-
2018
- 2018-07-11 AR ARP180101929A patent/AR112757A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123932T1 (en) | STRUCTURES OF POLYSPECIFIC ANTIBODY | |
| PE20142406A1 (en) | ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES | |
| CY1124806T1 (en) | ENANTI-CD40 ANTIBODIES AND USES THEREOF | |
| MX2025006260A (en) | Dnase variants | |
| EP3950941A3 (en) | Dnase polypeptide variants | |
| SA518400424B1 (en) | Antibody molecules for cancer treatment | |
| PE20190563A1 (en) | OPTIMIZED MINI-DISTROPHIN GENES AND EXPRESSION CASSETS AND THEIR USE | |
| MX420947B (en) | CONSTRUCTS THAT SPECIFICALLY RECOGNIZE GLYPICAN 3 AND THEIR USES. | |
| BR112018070934A2 (en) | immunomodulatory proteins, single ligand variants and uses thereof | |
| CO2018009120A2 (en) | Optimized factor viii genes | |
| BR112018074463A2 (en) | anti-tim-3 antibodies and methods of use. | |
| BR112017014031A2 (en) | Recombinant n-oligosaccharyl transferase, recombinant n-oligosaccharyl transferase mutant, nucleic acid, host cell, and method for producing a bioconjugate. | |
| BR112018072946A2 (en) | fusion proteins to gdf15 and uses thereof | |
| EP3741848A3 (en) | Protease variants and polynucleotides encoding same | |
| CR20190072A (en) | Bispecific antibody-like binding proteins specifically binding to cd3 and cd123 | |
| MX2023001119A (en) | VARIANTS OF ENZYMES AND POLINUCLEOTIDES THAT CODE THEM. | |
| MX2021010668A (en) | Cytokine fusion proteins. | |
| BR112017023692A2 (en) | glycan-dependent immunotherapeutic molecules | |
| AR102950A1 (en) | LIPASE AND POLINUCLEOTIDE VARIANTS CODING THEM | |
| MX2019000743A (en) | SERINPROTEASE AND POLINUCLEOTID VARIANTS CODING THEM. | |
| CL2018000164A1 (en) | Recombinant vector of the orf virus. | |
| EP3964575A3 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| BR112016025898A2 (en) | Drimenol Synthases and Method for Producing Drimenol | |
| UY36617A (en) | IMMUNOGENIC FUSION PROTEINS FOR CANCER TREATMENT | |
| CO2018007442A2 (en) | Cancer Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |